This infographic highlights tips to overcome challenges in the areas of PK analysis, large molecule analysis by LC–MS/MS and prodrug analysis.
In this interview, we talk to Mary Lame (Principal Applications Scientist, Waters Corporation; MA, USA) who discusses the key challenges scientists face when developing robust peptide bioanalytical assays.
This infographic highlights tips and tricks for overcoming five key bioanalytical challenges in peptide bioanalysis sample preparation.
2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies’ inputs on bioanalysis, biomarkers and immunogenicity)
This part of the 2018 White Paper published in Bioanalysis focuses on the recommendations for PK, PD and ADA assays by hybrid LBA/LCMS and regulatory agencies’ input.
In this Bioanalysis Zone interview, Shane Needham (Alturas Analytics; ID, USA) discusses the advantages and disadvantages of the technologies employed by Alturas Analytics, including microflow LC–MS.
“There are, in essence, two schools of thought that I can perceive when discussions occur on the topic of appropriate purity of the laboratory water and various solvents, additives and reagents for any given stage of a quantitative bioanalytical procedure.” Find out more from Robert MacNeill (Envigo) in this editorial column.
As part of our ‘In the Zone’ feature on drug metabolism, we present the top 6 tips for LC–MS for drug metabolism studies. Find out more about best practice tip and tricks for LC–MS in this helpful infographic from MilliporeSigma (MO, USA).
Improving selectivity and sensitivity of protein quantitation by LC–HR–MS/MS: determination of somatropin in rat plasma
Find out more this method to improve selectivity and sensitivity of protein quantitation by LC–HR–MS/MS in this free article from Bioanalysis.
In this interview with Ragu Ramanathan (Pfizer; NY, USA), Ragu describes his current research focuses in measuring and quantitating drugs and metabolites in animal and human samples. Ragu discusses the key challenges associated with studying drug/drug interactions (DDI), the benefits of current technologies available for studying DDI and what to expect from the upcoming Special Focus Issue from Bioanalysis on ‘Novel LC–MS assays impacting CYP and transporter DDI evaluation’.
Opportunities and challenges for hybrid immunoaffinity LC–MS approach for quantitative analysis of protein biomarkers
Learn more about opportunities and challenges for hybrid immunoaffinity LC–MS approach for quantitative analysis of protein biomarkers in this article from Future Science OA.